NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Saturday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NeuroMetrix stock opened at $4.37 on Friday. The business has a fifty day simple moving average of $4.06 and a two-hundred day simple moving average of $3.93. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73. The company has a market capitalization of $8.91 million, a price-to-earnings ratio of -0.95 and a beta of 2.18.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.